Heightened merger scrutiny in the life sciences sector is reshaping how transactions are structured, evaluated and defended, as authorities intensify their focus on pipeline overlaps across R&D and manufacturing value chains.
This session will examine current trends in life science M&A, novel approaches to assessing horizontal and vertical concentration and the core implications of antitrust M&A risk for your overall transaction strategy and design.
- How are competition authorities currently assessing life science M&As? What types of deals are attracting the most scrutiny?
- How should companies evaluate antitrust risk when acquiring early-stage or pipeline assets that are not yet on the market? - When does vertical/horizontal integration create meaningful competition risk?
- When during an M&A process should antitrust considerations influence the deal structure, valuation and conditionality?